UniQure Shares Plunge 37% After FDA Feedback And FY25 Results

uniQure N.V. (QURE) shares tumbled 36.58 percent to $9.91, down $5.72 on Monday, after the company reported a full-year net loss and disclosed FDA feedback indicating that current Phase 1/2 data for AMT-130 in Huntington's disease are insufficient to support a marketing application.The stock is currently trading at $9.91, compared with a previous close of $15.63. It opened at $9.19 and has traded between $8.96 and $10.28 during the session on the Nasdaq. Trading volume stands at 8.53 million shares, well a ...